{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T18:13:38Z","timestamp":1788632018351,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T00:00:00Z","timestamp":1788566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100010793","name":"Pfizer Japan Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncol Ther"],"DOI":"10.1007\/s40487-026-00459-2","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:50:26Z","timestamp":1788587426000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Testing Landscape and Costs of Companion Diagnostics and Comprehensive Genomic Profiling Across Nine Solid Tumors in Japan: A 10-Year Analysis"],"prefix":"10.1007","author":[{"given":"Kuniko","family":"Sunami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5880-1615","authenticated-orcid":false,"given":"Sona-Sanae","family":"Aoyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanae","family":"Togo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,5]]},"reference":[{"key":"459_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0703-1","author":"ER Malone","year":"2020","unstructured":"Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med. 2020;12. https:\/\/doi.org\/10.1186\/s13073-019-0703-1.","journal-title":"Genome Med"},{"key":"459_CR2","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/jalm\/jfad091","volume":"9","author":"MY Tjota","year":"2024","unstructured":"Tjota MY, Segal JP, Wang P. Clinical utility and benefits of comprehensive genomic profiling in cancer. J Appl Lab Med. 2024;9:76\u201391. https:\/\/doi.org\/10.1093\/jalm\/jfad091.","journal-title":"J Appl Lab Med"},{"key":"459_CR3","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1158\/2159-8290.CD-22-0417","volume":"12","author":"T Kohno","year":"2022","unstructured":"Kohno T, Kato M, Kohsaka S, et\u00a0al. C-CAT: the national datacenter for cancer genomic medicine in Japan. Cancer Discov. 2022;12:2509\u201315. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-0417.","journal-title":"Cancer Discov"},{"key":"459_CR4","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/cas.16065","volume":"115","author":"H Kage","year":"2024","unstructured":"Kage H, Akiyama N, Chang H, et\u00a0al. Patient survey on cancer genomic medicine in Japan under the national health insurance system. Cancer Sci. 2024;115:954\u201362. https:\/\/doi.org\/10.1111\/cas.16065.","journal-title":"Cancer Sci"},{"key":"459_CR5","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1111\/cas.14754","volume":"112","author":"Y Mukai","year":"2021","unstructured":"Mukai Y, Ueno H. Establishment and implementation of cancer genomic medicine in Japan. Cancer Sci. 2021;112:970\u20137. https:\/\/doi.org\/10.1111\/cas.14754.","journal-title":"Cancer Sci"},{"key":"459_CR6","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1111\/cas.15837","volume":"114","author":"K Hagio","year":"2023","unstructured":"Hagio K, Kikuchi J, Takada K, et\u00a0al. Assessment for the timing of comprehensive genomic profiling tests in patients with advanced solid cancers. Cancer Sci. 2023;114:3385\u201395. https:\/\/doi.org\/10.1111\/cas.15837.","journal-title":"Cancer Sci"},{"key":"459_CR7","doi-asserted-by":"publisher","DOI":"10.1200\/po.23.00292","author":"J Yorio","year":"2024","unstructured":"Yorio J, Lofgren KT, Lee JK, et\u00a0al. Association of timely comprehensive genomic profiling with precision oncology treatment use and patient outcomes in advanced non-small-cell lung cancer. JCO Precis Oncol. 2024;8. https:\/\/doi.org\/10.1200\/po.23.00292.","journal-title":"JCO Precis Oncol"},{"key":"459_CR8","unstructured":"Jeremias SKylar. Lack of CGP testing may result in missed therapy options in NSCLC | AJMC; 2022. https:\/\/www.ajmc.com\/view\/lack-of-cgp-testing-may-result-in-missed-therapy-options-in-nsclc. Accessed 4 Feb 2026"},{"key":"459_CR9","doi-asserted-by":"publisher","unstructured":"Ebi H, Bando H. Precision oncology and the universal health coverage system in Japan. JCO Precis Oncol. 2019;1\u201312. https:\/\/doi.org\/10.1200\/po.19.00291","DOI":"10.1200\/po.19.00291"},{"key":"459_CR10","doi-asserted-by":"publisher","first-page":"e2323336","DOI":"10.1001\/jamanetworkopen.2023.23336","volume":"6","author":"J Matsubara","year":"2023","unstructured":"Matsubara J, Mukai K, Kondo T, et\u00a0al. First-line genomic profiling in previously untreated advanced solid tumors for identification of targeted therapy opportunities. JAMA Netw Open. 2023;6:e2323336\u2013e2323336. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.23336.","journal-title":"JAMA Netw Open"},{"key":"459_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/B978-0-12-813539-6.00019-5","volume-title":"Companion and complementary diagnostics: from biomarker discovery to clinical implementation","author":"R Shimazawa","year":"2019","unstructured":"Shimazawa R, Ikeda M. Regulatory requirements for companion diagnostics\u2014Japan. In: Companion and complementary diagnostics: from biomarker discovery to clinical implementation. Academic Press; 2019. p. 365\u201379. https:\/\/doi.org\/10.1016\/B978-0-12-813539-6.00019-5."},{"key":"459_CR12","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/pin.13023","volume":"70","author":"Y Yatabe","year":"2020","unstructured":"Yatabe Y, Sunami K, Goto K, et\u00a0al. Multiplex gene-panel testing for lung cancer patients. Pathol Int. 2020;70:921\u201331. https:\/\/doi.org\/10.1111\/pin.13023.","journal-title":"Pathol Int"},{"key":"459_CR13","unstructured":"Companion Diagnostics. Pharmaceuticals and Medical Devices Agency. https:\/\/www.pmda.go.jp\/english\/rs-sb-std\/rs\/0027.html. Accessed 13 Jul 2026."},{"key":"459_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12282-015-0586-y","volume":"23","author":"Y Tazawa","year":"2016","unstructured":"Tazawa Y. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan. Breast Cancer. 2016;23:19\u201323. https:\/\/doi.org\/10.1007\/s12282-015-0586-y.","journal-title":"Breast Cancer"},{"key":"459_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70162","volume":"18","author":"K Saito","year":"2025","unstructured":"Saito K, Narukawa M. Bridging gaps in oncology: comparative analysis of development and approval pathways for anticancer drugs and companion diagnostic in the United States and Japan. Clin Transl Sci. 2025;18:e70162. https:\/\/doi.org\/10.1111\/cts.70162.","journal-title":"Clin Transl Sci"},{"key":"459_CR16","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.3390\/curroncol30020180","volume":"30","author":"BS Sheffield","year":"2023","unstructured":"Sheffield BS, Eaton K, Emond B, et\u00a0al. Cost savings of expedited care with upfront next-generation sequencing testing versus single-gene testing among patients with metastatic non-small cell lung cancer based on current Canadian practices. Curr Oncol. 2023;30:2348\u201365. https:\/\/doi.org\/10.3390\/curroncol30020180.","journal-title":"Curr Oncol"},{"key":"459_CR17","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1080\/13696998.2022.2080463","volume":"25","author":"D Proudman","year":"2022","unstructured":"Proudman D, DeVito NC, Belinson S, et\u00a0al. Comprehensive genomic profiling in advanced\/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use. J Med Econ. 2022;25:817\u201325. https:\/\/doi.org\/10.1080\/13696998.2022.2080463.","journal-title":"J Med Econ"},{"key":"459_CR18","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1080\/13696998.2018.1549056","volume":"22","author":"J Signorovitch","year":"2019","unstructured":"Signorovitch J, Zhou Z, Ryan J, Anhorn R, Chawla A. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer. J Med Econ. 2019;22:140\u201350. https:\/\/doi.org\/10.1080\/13696998.2018.1549056.","journal-title":"J Med Econ"},{"key":"459_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.vhri.2023.08.006","volume":"39","author":"O Gamboa","year":"2024","unstructured":"Gamboa O, Bonilla CE, Quitian D, Torres GF, Buitrago G, Cardona AF. Cost-effectiveness of comprehensive genomic profiling in patients with non\u2013small cell lung cancer for the Colombian health system. Value Health Reg Issues. 2024;39:115\u201325. https:\/\/doi.org\/10.1016\/j.vhri.2023.08.006.","journal-title":"Value Health Reg Issues"},{"key":"459_CR20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40801-022-00296-5","volume":"9","author":"T Laurent","year":"2022","unstructured":"Laurent T, Simeone J, Kuwatsuru R, et\u00a0al. Context and considerations for use of two Japanese real-world databases in Japan: Medical Data Vision and Japanese Medical Data Center. Drugs. 2022;9:175\u201387. https:\/\/doi.org\/10.1007\/s40801-022-00296-5.","journal-title":"Drugs Real World Outcomes"},{"key":"459_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s40801-023-00371-5","volume":"10","author":"T Laurent","year":"2023","unstructured":"Laurent T, Lambrelli D, Wakabayashi R, Hirano T, Kuwatsuru R. Strategies to address current challenges in real-world evidence generation in Japan. Drugs Real World Outcomes. 2023;10:167\u201376. https:\/\/doi.org\/10.1007\/s40801-023-00371-5.","journal-title":"Drugs Real World Outcomes"},{"key":"459_CR22","unstructured":"MDV. Medical Data Vision Co., Ltd. 2025. https:\/\/en.mdv.co.jp\/about-us\/. Accessed 4 Feb 2026."},{"key":"459_CR23","doi-asserted-by":"publisher","unstructured":"Tanaka S, Seto K, Kawakami K. Pharmacoepidemiology in Japan: medical databases and research achievements. J Pharm Health Care Sci. 2015;1:16. https:\/\/doi.org\/10.1186\/s40780-015-0016-5.","DOI":"10.1186\/s40780-015-0016-5"},{"key":"459_CR24","unstructured":"JMDC. JMDC Claims Database\u2014JMDC Inc. 2025. https:\/\/www.jmdc.co.jp\/En\/Jmdc-Claims-Database\/. Accessed 4 Feb 2026."},{"key":"459_CR25","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/jgf2.367","volume":"21","author":"K Nagai","year":"2020","unstructured":"Nagai K, Tanaka T, Kodaira N, Kimura S, Takahashi Y, Nakayama T. Data resource profile: JMDC claims databases sourced from medical institutions. J Gen Fam Med. 2020;21:211\u20138. https:\/\/doi.org\/10.1002\/jgf2.367.","journal-title":"J Gen Fam Med"},{"key":"459_CR26","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.21037\/tau-22-396","volume":"11","author":"K Fujita","year":"2022","unstructured":"Fujita K, Suzuki H, Hinata N, et\u00a0al. Management of patients with advanced prostate cancer in Japan: \u201creal-world\u201d consideration of the results from the Advanced Prostate Cancer Consensus Conference. Transl Androl Urol. 2022;11:1771\u201385. https:\/\/doi.org\/10.21037\/tau-22-396.","journal-title":"Transl Androl Urol"},{"key":"459_CR27","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/iju.15545","volume":"31","author":"Y Kohjimoto","year":"2023","unstructured":"Kohjimoto Y, Uemura H, Yoshida M, et\u00a0al. Japanese clinical practice guidelines for prostate cancer 2023. Int J Urol. 2023;31:1180\u2013222. https:\/\/doi.org\/10.1111\/iju.15545.","journal-title":"Int J Urol"},{"key":"459_CR28","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1093\/jjco\/hyae079","volume":"54","author":"T Kawai","year":"2024","unstructured":"Kawai T, Onozawa M, Taguchi S, et\u00a0al. Changes in the trends of initial treatment for newly diagnosed prostate cancer in Japan: a nationwide multi-institutional study. Jpn J Clin Oncol. 2024;54:1045\u201351. https:\/\/doi.org\/10.1093\/jjco\/hyae079.","journal-title":"Jpn J Clin Oncol"},{"key":"459_CR29","doi-asserted-by":"publisher","first-page":"7272","DOI":"10.3390\/curroncol29100573","volume":"29","author":"M Kanai","year":"2022","unstructured":"Kanai M. Current clinical practice of precision medicine using comprehensive genomic profiling tests in biliary tract cancer in Japan. Curr Oncol. 2022;29:7272\u201384. https:\/\/doi.org\/10.3390\/curroncol29100573.","journal-title":"Curr Oncol"},{"key":"459_CR30","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1093\/jjco\/hyaf052","volume":"55","author":"N Okano","year":"2025","unstructured":"Okano N, Pirozzi A, Abidoye O, et\u00a0al. Systemic therapy for pretreated advanced biliary tract cancer: past developments and recent advances. Jpn J Clin Oncol. 2025;55:675\u201390. https:\/\/doi.org\/10.1093\/jjco\/hyaf052.","journal-title":"Jpn J Clin Oncol"},{"key":"459_CR31","unstructured":"Haigan. Lung Cancer Treatment Guidelines 2024 Edition; 2024. https:\/\/www.haigan.gr.jp\/publication\/guideline\/examination\/2024\/1\/2\/240102070100.html. Accessed 4 Feb 2026."},{"key":"459_CR32","doi-asserted-by":"publisher","unstructured":"Riely GJ, Wood DE, Ettinger DS, Aisner DL, Akerley W, Bauman JR, et\u00a0al. Non\u2013small cell lung cancer, version 4.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22:249\u201374. https:\/\/doi.org\/10.6004\/jnccn.2204.0023.","DOI":"10.6004\/jnccn.2204.0023"},{"key":"459_CR33","unstructured":"HGPI. Health and Global Policy Institute (HGPI) The global health policy think tank; 2025. https:\/\/hgpi.org\/en\/. Accessed 4 Feb 2026."},{"key":"459_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102443","volume":"69","author":"A Hernando-Calvo","year":"2024","unstructured":"Hernando-Calvo A, Nguyen P, Bedard PL, et\u00a0al. Impact on costs and outcomes of multi-gene panel testing for advanced solid malignancies: a cost-consequence analysis using linked administrative data. EClinicalMedicine. 2024;69:102443. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102443.","journal-title":"EClinicalMedicine"},{"key":"459_CR35","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1080\/13696998.2018.1450261","volume":"21","author":"AA Dalal","year":"2018","unstructured":"Dalal AA, Guerin A, Mutebi A, Culver KW. Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer. J Med Econ. 2018;21:649\u201355. https:\/\/doi.org\/10.1080\/13696998.2018.1450261.","journal-title":"J Med Econ"},{"key":"459_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e37867","volume":"10","author":"N Shiraiwa","year":"2024","unstructured":"Shiraiwa N, Kano S. Cost-effectiveness of multigene sequencing test and treatment for metastatic non-small cell lung cancer: a unique setting in the initial adoption phase in Japan allowing testing only after standard treatment. Heliyon. 2024;10:e37867. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37867.","journal-title":"Heliyon"},{"key":"459_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/life11080796","author":"Y Yoshii","year":"2021","unstructured":"Yoshii Y, Okazaki S, Takeda M. Current status of next-generation sequencing-based cancer genome profiling tests in Japan and prospects for liquid biopsy. Life (Basel). 2021;11.\u00a0https:\/\/doi.org\/10.3390\/life11080796.","journal-title":"Life (Basel)"},{"key":"459_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1025367","volume":"13","author":"B Thapa","year":"2023","unstructured":"Thapa B, Ahmed G, Szabo A, et\u00a0al. Comprehensive genomic profiling: does timing matter? Front Oncol. 2023;13:1025367. https:\/\/doi.org\/10.3389\/fonc.2023.1025367.","journal-title":"Front Oncol"},{"key":"459_CR39","unstructured":"Haigan. Lung Cancer Treatment Guidelines 2025 Edition; 2025. https:\/\/www.haigan.gr.jp\/publication\/guideline\/examination\/2025\/1\/1\/250101060100.html. Accessed 4 Feb 2026"},{"key":"459_CR40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.36401\/JIPO-24-11","volume":"8","author":"S Limaye","year":"2025","unstructured":"Limaye S, Deshmukh J, Rohatagi N, et\u00a0al. Usefulness of comprehensive genomic profiling in clinical decision-making in oncology: a systematic review. J Immunother Precis Oncol. 2025;8:55\u201363. https:\/\/doi.org\/10.36401\/JIPO-24-11.","journal-title":"J Immunother Precis Oncol"},{"key":"459_CR41","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10147-020-01831-6","volume":"26","author":"Y Naito","year":"2020","unstructured":"Naito Y, Aburatani H, Amano T, et\u00a0al. Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1). Int J Clin Oncol. 2020;26:233\u201383. https:\/\/doi.org\/10.1007\/s10147-020-01831-6.","journal-title":"Int J Clin Oncol"},{"key":"459_CR42","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1111\/cas.70077","volume":"116","author":"J Matsubara","year":"2025","unstructured":"Matsubara J, Mukai K, Kondo T, et\u00a0al. First-line genomic profiling in previously untreated advanced solid tumors: 1-year follow-up of the FIRST-Dx study. Cancer Sci. 2025;116:1908\u201319. https:\/\/doi.org\/10.1111\/cas.70077.","journal-title":"Cancer Sci"},{"key":"459_CR43","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/jjco\/hyaf016","volume":"55","author":"C Morizane","year":"2025","unstructured":"Morizane C, Ueno M, Ikeda M, Okusaka T, Ishii H, Furuse J. Update for: new developments in systemic therapy for advanced biliary tract cancer. Jpn J Clin Oncol. 2025;55:210\u20138. https:\/\/doi.org\/10.1093\/jjco\/hyaf016.","journal-title":"Jpn J Clin Oncol"},{"key":"459_CR44","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.jmoldx.2025.05.011","volume":"27","author":"S Spencer","year":"2025","unstructured":"Spencer S, Ye W, Peng S, Zou D. Cost-effectiveness analysis of comprehensive genomic profiling in patients with advanced non\u2013small-cell lung cancer using real-world data. J Mol Diagn. 2025;27:850\u20138. https:\/\/doi.org\/10.1016\/j.jmoldx.2025.05.011.","journal-title":"J Mol Diagn"},{"key":"459_CR45","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1080\/13696998.2023.2202599","volume":"26","author":"W Tang","year":"2023","unstructured":"Tang W, Hanada K, Motoo Y, et\u00a0al. Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan. J Med Econ. 2023;26:614\u201326. https:\/\/doi.org\/10.1080\/13696998.2023.2202599.","journal-title":"J Med Econ"},{"key":"459_CR46","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/po.20.00540","volume":"5","author":"MJ Harvey","year":"2021","unstructured":"Harvey MJ, Cunningham R, Sawchyn B, et\u00a0al. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small-cell lung cancer. JCO Precis Oncol. 2021;5:1611\u201324. https:\/\/doi.org\/10.1200\/po.20.00540.","journal-title":"JCO Precis Oncol"},{"key":"459_CR47","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3747\/co.27.5995","volume":"27","author":"KM Johnston","year":"2020","unstructured":"Johnston KM, Sheffield BS, Yip S, Lakzadeh P, Qian C, Nam J. Comprehensive genomic profiling for non-small-cell lung cancer: health and budget impact. Curr Oncol. 2020;27:569\u201377. https:\/\/doi.org\/10.3747\/co.27.5995.","journal-title":"Curr Oncol"},{"key":"459_CR48","first-page":"368","volume":"51","author":"Y Tsukumo","year":"2024","unstructured":"Tsukumo Y, Inoue T. [Current status and regulatory issues of companion diagnostics in Japan]. Gan To Kagaku Ryoho. 2024;51:368\u201377.","journal-title":"Gan To Kagaku Ryoho"}],"container-title":["Oncology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00459-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40487-026-00459-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40487-026-00459-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T18:02:16Z","timestamp":1788631336000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40487-026-00459-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,5]]},"references-count":48,"alternative-id":["459"],"URL":"https:\/\/doi.org\/10.1007\/s40487-026-00459-2","relation":{},"ISSN":["2366-1070","2366-1089"],"issn-type":[{"value":"2366-1070","type":"print"},{"value":"2366-1089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,5]]},"assertion":[{"value":"16 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kuniko Sunami has received advisory fees from Pfizer Japan Inc. in relation to this study. Sona-Sanae Aoyagi is an employee of Pfizer Japan Inc. and holds stock ownership in the company. Masashi Mikami is an employee of Pfizer Japan Inc. Kanae Togo was an employee of Pfizer Japan Inc. at the time of the study and holds stock ownership in the company. Kuniko Sunami, Sona-Sanae Aoyagi, Masashi Mikami, and Kanae Togo have no other conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was a secondary analysis utilizing structured, anonymized data and did not involve the collection of new patient data or any personal identifiable information. According to the Ethical Guidelines for Medical and Biological Research Involving Human Subjects (2021 revision by the Ministry of Education, Culture, Sports, Science and Technology [MEXT]) and the Ministry of Health, Labor and Welfare (MHLW), studies utilizing anonymized data do not require approval from an Institutional Review Board (IRB) or Ethics Committee (EC). The study investigators had full permission from the database owners to access and use the Medical Data Vision (MDV) Co., Ltd. Tokyo, Japan and the JMDC Inc. (JMDC), Tokyo, Japan claims databases. Patient consent was waived due to the study using only anonymized data.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}